Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen: a valuable clinical tool.

J E Oesterling1

  • 1Department of Urology, Mayo Clinic.

Oncology (Williston Park, N.Y.)
|April 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

The Journal of urology·1999
Same author

Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

The Journal of urology·1999
Same author

Have complication rates decreased after treatment for localized prostate cancer?

The Journal of urology·1999
Same author

Reference ranges for serum prostate-specific antigen in black and white men without cancer.

Urology·1998
Same author

Understanding artificial neural networks and exploring their potential applications for the practicing urologist.

Urology·1998
Same author

Screening digital rectal examination and prostate cancer mortality: a population-based case-control study.

Urology·1998
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Serum prostate-specific antigen (PSA) alone is not a reliable screening tool for prostate cancer. However, PSA combined with other methods like digital rectal examination (DRE) aids early detection and monitoring after treatment.

Area of Science:

  • Urology
  • Oncology
  • Medical Diagnostics

Background:

  • Benign prostatic hyperplasia (BPH) affects a significant portion of the male population.
  • Prostate cancer diagnosis and staging rely on various clinical and laboratory markers.
  • Early detection of prostate cancer is crucial for effective treatment and improved patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of serum prostate-specific antigen (PSA) as a standalone screening tool for prostate cancer.
  • To assess the role of PSA in conjunction with other diagnostic methods for early prostate cancer detection.
  • To determine the utility of PSA in staging prostate cancer and predicting outcomes after treatment.

Main Methods:

  • Analysis of serum PSA concentrations in patients with BPH and prostate cancer.

Related Experiment Videos

  • Correlation of PSA levels with clinical and pathological staging of prostate cancer.
  • Evaluation of PSA as a predictor of bone scan results in untreated prostate cancer patients.
  • Assessment of PSA's sensitivity and prognostic value in monitoring patients post-definitive therapy.

    • Main Results:

    • Elevated serum PSA is observed in only about 30% of BPH patients, limiting its use as a sole screening tool.
    • PSA, when combined with digital rectal examination (DRE) and/or transrectal ultrasound, shows potential for early detection programs.
    • While correlated with clinical and pathological stage, PSA alone is not reliable for individual staging.
    • Low preoperative PSA levels predict negative radionuclide bone scans in untreated prostate cancer.
    • Post-therapy, PSA serves as a highly sensitive tumor marker, accurately reflecting tumor status and predicting outcomes.

    Conclusions:

    • Serum PSA is not effective as a standalone screening tool for prostate cancer due to limited sensitivity in BPH.
    • Combining PSA testing with DRE and/or transrectal ultrasound can enhance early prostate cancer detection efforts.
    • PSA is valuable in predicting negative bone scans pre-treatment and serves as a sensitive prognostic marker for monitoring treatment response and patient outcomes.